We are happy to share that CLS Americas has entered into an agreement with Genesis Research, LLC, an affiliate of Unio Health Partners, to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.

We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.

We are happy to share that HALO Diagnostics, Inc. (HALO Dx) will evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients.

CLS Americas announces the full twenty patients have been safely treated in the Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

Our CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik, explain how the TRANBERG® Thermal Therapy Systems have been designed for precise and safe focal therapy of soft tissue, such as the prostate gland, and what kind of research CLS is now supporting.

CEO Dan J. Mogren introduces our support for Movember. This annual campaign is all about raising awareness around male health, and specifically around prostate cancer. It is one of the most common cancer forms among men, but more can be done to spread knowledge about the disease.

Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.

We are proud to announce that CLS has received FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery!

Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.

CLS Americas today announced the first patient has been safely treated in its recently announced 20-patient, Phase I clinical study.

Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Radboud University Medical Center (Radboudumc) in Nijmegen in the Netherlands has obtained approval from its ethics committee for its Investigator Initiated Trial (IIT) to evaluate the safety and feasibility of magnetic resonance guided focused laser ablation (MRgFLA) as a focal therapy treatment for localized prostate cancer in low to intermediate risk patients, using the TRANBERG® Thermal Therapy System with Thermoguide™ Workstation.